phytic acid has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies
Phytic Acid: Complexing agent for removal of traces of heavy metal ions. It acts also as a hypocalcemic agent.
myo-inositol hexakisphosphate : A myo-inositol hexakisphosphate in which each hydroxy group of myo-inositol is monophosphorylated.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deliliers, GL | 1 |
| Servida, F | 1 |
| Fracchiolla, NS | 1 |
| Ricci, C | 1 |
| Borsotti, C | 1 |
| Colombo, G | 1 |
| Soligo, D | 1 |
1 other study available for phytic acid and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Effect of inositol hexaphosphate (IP(6)) on human normal and leukaemic haematopoietic cells.
Topics: Cell Cycle; Cell Death; Cell Division; DNA, Neoplasm; Dose-Response Relationship, Drug; Gene Express | 2002 |